OTCMKTS:ARTH Arch Therapeutics (ARTH) Stock Forecast, Price & News $1.30 0.00 (0.00%) (As of 09/29/2023 08:54 PM ET) Add Compare Share Share Today's Range$1.30▼$1.3450-Day Range$0.55▼$2.6052-Week Range$0.48▼$10.80Volume600 shsAverage Volume1,587 shsMarket Capitalization$4.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest About Arch Therapeutics (OTCMKTS:ARTH) StockArch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.Read More ARTH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARTH Stock News HeadlinesSeptember 13, 2023 | finance.yahoo.comArch Therapeutics Provides AC5® Commercialization UpdateSeptember 8, 2023 | finanznachrichten.deArch Therapeutics, Inc.: Arch Therapeutics Completes Financing as Bridge to UplistingOctober 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. September 7, 2023 | finance.yahoo.comArch Therapeutics Completes Financing as Bridge to UplistingJuly 8, 2023 | health.usnews.comDr. Arth PatelJune 13, 2023 | travel.usnews.comDouble ArchApril 25, 2023 | finance.yahoo.comArch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)April 5, 2023 | finance.yahoo.comDedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In EffectOctober 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. March 20, 2023 | investing.comArch Therapeutics Inc (ARTHD)March 9, 2023 | finance.yahoo.comArch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid ServicesMarch 7, 2023 | finance.yahoo.comArch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government FacilitiesFebruary 23, 2023 | benzinga.comArch Therapeutics Inc Stock (OTC:ARTHD), Earnings Estimates, EPS, and RevenueJanuary 24, 2023 | msn.comWound products developer Arch Therapeutics files for uplisting, $35M offering (update)January 18, 2023 | finanznachrichten.deArch Therapeutics, Inc.: Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National ExchangeJanuary 18, 2023 | finance.yahoo.comArch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound SystemJanuary 17, 2023 | finance.yahoo.comArch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National ExchangeDecember 5, 2022 | finance.yahoo.comThe Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound SystemOctober 20, 2022 | seekingalpha.comARTH Arch Therapeutics, Inc.October 18, 2022 | yahoo.comKey Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) FallOctober 11, 2022 | finance.yahoo.comArch Therapeutics’ AC5® Advanced Wound System to be Presented with Honors at 2022 Symposium on Advanced Wound Care (SAWC) FallSeptember 23, 2022 | finance.yahoo.comArch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support ProgramSeptember 16, 2022 | finance.yahoo.comArch Therapeutics Announces Intent to Uplist from OTC to a National ExchangeSeptember 7, 2022 | finance.yahoo.comArch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound SystemJuly 14, 2022 | benzinga.comArch Therapeutics (OTC:ARTH), Short Interest ReportJuly 7, 2022 | finance.yahoo.comArch Therapeutics Raises Approximately $3.5 Million in Convertible Note FinancingJune 22, 2022 | finance.yahoo.comArch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling ChannelSee More Headlines Receive ARTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARTH Company Calendar Last Earnings8/11/2023Today10/02/2023Next Earnings (Estimated)12/25/2023Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ARTH Previous SymbolNASDAQ:ARTH CUSIPN/A CIK1537561 Webwww.archtherapeutics.com Phone(617) 431-2313FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,280,000.00 Net Margins-16,959.23% Pretax Margin-16,956.59% Return on EquityN/A Return on Assets-281.18% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.02 Sales & Book Value Annual Sales$20,000.00 Price / Sales200.85 Cash FlowN/A Price / Cash FlowN/A Book Value($3.36) per share Price / Book-0.39Miscellaneous Outstanding Shares3,090,000Free Float2,955,000Market Cap$4.02 million OptionableNot Optionable Beta0.65 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Terrence W. Norchi M.D. (Age 58)Co-Founder, Chairman, Pres & CEO Comp: $450.5kMr. Michael S. Abrams (Age 53)CFO & Treasurer Comp: $325kMr. Daniel M. Yrigoyen (Age 53)VP of Sales Comp: $316.67kDr. Rutledge Ellis-Behnke Ph.D.Co-Founder & Scientific AdvisorKey CompetitorsEKIMASOTCMKTS:ASNBQuoin PharmaceuticalsNASDAQ:QNRXSeaStar MedicalNASDAQ:ICUInVivo TherapeuticsNASDAQ:NVIVUnited American HealthcareOTCMKTS:UAHCView All Competitors ARTH Stock - Frequently Asked Questions How have ARTH shares performed in 2023? Arch Therapeutics' stock was trading at $0.0260 at the beginning of 2023. Since then, ARTH stock has increased by 4,900.0% and is now trading at $1.30. View the best growth stocks for 2023 here. Are investors shorting Arch Therapeutics? Arch Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 3,700 shares, an increase of 76.2% from the August 31st total of 2,100 shares. Based on an average daily trading volume, of 14,500 shares, the short-interest ratio is presently 0.3 days. View Arch Therapeutics' Short Interest. When is Arch Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, December 25th 2023. View our ARTH earnings forecast. How were Arch Therapeutics' earnings last quarter? Arch Therapeutics, Inc. (OTCMKTS:ARTH) announced its quarterly earnings data on Friday, August, 11th. The biotechnology company reported ($1.42) earnings per share (EPS) for the quarter. The biotechnology company earned $0.01 million during the quarter. What other stocks do shareholders of Arch Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Sciences (AVXL), POET Technologies (POETF), Aptose Biosciences (APTO), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), Bellerophon Therapeutics (BLPH), Sorrento Therapeutics (SRNE), Biocept (BIOC) and Aurinia Pharmaceuticals (AUPH). What is Arch Therapeutics' stock symbol? Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH." How do I buy shares of Arch Therapeutics? Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arch Therapeutics' stock price today? One share of ARTH stock can currently be purchased for approximately $1.30. How much money does Arch Therapeutics make? Arch Therapeutics (OTCMKTS:ARTH) has a market capitalization of $4.02 million and generates $20,000.00 in revenue each year. How can I contact Arch Therapeutics? Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The official website for the company is www.archtherapeutics.com. The biotechnology company can be reached via phone at (617) 431-2313 or via email at investors@archtherapeutics.com. This page (OTCMKTS:ARTH) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arch Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.